Gossamer Bio, Inc.
GOSS · XNASCIK 1728117fmd_03NJMKSNDY90D5E7C1MFHJAG3XManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 0 | 115 | 48 |
| Realized investment gains (losses) | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 1 | 55 | 143 | 161 | 170 | 171 | 135 | 138 | 174 |
| Total operating expenses | 7 | 149 | 186 | 234 | 216 | 219 | 184 | 175 | 219 |
| Operating income | (7) | (149) | (186) | (234) | (216) | (219) | (184) | (60) | (171) |
| Interest expense | – | 0 | 2 | 13 | 19 | 14 | 14 | 12 | 11 |
| Interest and investment income | – | 2 | 6 | 3 | 1 | 2 | 2 | 2 | 2 |
| Other non-operating income (expense) | (0) | 2 | 6 | (0) | (18) | (11) | 4 | 4 | 0 |
| Income before taxes | 7 | (147) | (180) | (243) | (234) | (229) | (180) | (56) | (170) |
| Income tax expense | 0 | 0 | 0 | – | – | 0 | 0 | 1 | (0) |
| Net income from continuing operations | 7 | (147) | (180) | – | – | (229) | (180) | (57) | (170) |
| Net income | (7) | (147) | (180) | (243) | (234) | (229) | (180) | (57) | (170) |